Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

8.375 +0.005 (+0.06%)
Streaming Delayed Price Updated: 12:56 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vir Biotechnology Inc

< Previous 1 2 Next >
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
From laggards to leaders: Small caps on the rise
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains. 
Via MarketBeat
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
– Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company’s confidence in its approach to a functional cure for HBV – 
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.